As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.
July 2017
A comprehensive review was initiated on hemibody irradiation for patients with solid tumors with an emphasis on bone metastases to determine the efficacy and the toxicity of this treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5